

paper no 18

Sheet 1 of 3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY DOCKET NO.: 1038-1003 MIS:jb	SERIAL NO.: 09/462,816
	APPLICANT : Xiaomao Li et al	
	FILING DATE: April 5, 2000	GROUP: 1633 1635

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NO	DATE	NAME	CLASS	SUBCL.	FILING DATE
BW	5,620,896	April 1997	Herrmann et al	435	320.1	April 20, 1995

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BW	1	McIntosh K., Canock, R.M. - Respiratory Syncytial Virus (In: Fields B.N, Knipe, DM, editors. Virology. New York: Raven Press: 1990. 1045-1072)
	2	Heilman, C.A. - Respiratory Syncytial And Parainfluenza Viruses (J Infect. Dis. 1990, 161: 402 to 406)
	3	Wertz GW, Sullender WM - Approaches To Immunization Against Respiratory Syncytial Virus (Biotechnology 1992, 20: 151-176)
	4	Murphy, B. R. et al - An Update on Approaches to the Development of Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) Vaccines (Virus Res. 32: 13-36, 1994).
	5	Levine, S., Kleiber-France, R., and Paradiso, P.R. - Demonstration That Glycoprotein G Is The Attachment Protein Of Respiratory Syncytial Virus (J. Gen. Virol. 69, 2521-2524, 1987)
	6	Anderson, L.J., Hierholzer, J.C., Tsou, C., Hendry, R.M., Fernie, B.F., Stone, Y. and McIntosh, K. - Antigenic Characterization Of Respiratory Syncytial Virus Strains With Monoclonal Antibodies (J. Infect. Dis. 151, 626-633, 1985)
	7	Johnson et al. - Antigenic Relatedness Between Glycoproteins of Human Respiratory Syncytial Virus Subgroups A and B: Evaluation of the Contributions of F and G Glycoproteins to Immunity (J. Virol 1987, 61: 3163-3166)
	8	Crowe, J.E. - Current Approaches To The Development Of Vaccines Against Disease Caused By Respiratory Syncytial Virus (RSV) And Parainfluenza Virus (PIV) (Vaccine 1995, 13: 415-421)
	9	Kapikian, A.Z. et al - An Epidemiologic Study of Altered Clinical Reactivity To Respiratory Syncytial (RS) Virus Infection In Children Previously Vaccinated With An Inactivated RS Virus Vaccine (Am. J. Epidemiol. 89: 405-421, 1969)
	10	Kim, H.W., et al - Respiratory Syncytial Virus Disease In Infants Despite Prior Administration Of antigenic Inactivated Vaccine. (Am. J. Epidemiol. 89: 422-434, 1969)
BW	11	Murphy, B.R. et al - Dissociation Between Serum Neutralizing and Glycoprotein Antibody Responses Of Infants And Children Who Received Inactivated Respiratory Syncytial Virus Vaccine (J. Clin. Microbiol. 24: 197-202, 1986)
EXAMINER: <i>Brian A. [Signature]</i>		
DATE CONSIDERED: 7/22/02		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

* Will follow shortly

Sheet 2 of 3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO.: 1038-1003 MIS:jb	SERIAL NO : 09/462,816
	APPLICANT : Xiaomao Li et al	
	FILING DATE: April 5, 2000	GROUP: 1635 1633

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL	TRANSLATION	
							YES	NO
BW	16	WO 90/11092	04/Oct/90	PCT WIPO				
BW	17	WO 94/21797	29/Sept/94	PCT WIPO				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
BW	12	Vaux-Peretz, F. et al - Comparison Of The Ability Of Formalin-Inactivated Respiratory Syncytial Virus, Immunopurified F, G And N Proteins And Cell Lysate To Enhance Pulmonary Changes In Balb/c Mice (Vaccine 10: 113-118, 1992)						
	13	Openshaw, P.J. - Immunopathological Mechanisms In Respiratory Syncytial Virus Disease (Springer-Semin Immunopathol. 17: 187-201, 1995).						
	14	Alwan et al - Distinct Types of Lung Disease Caused By Functional Subsets Of Antiviral T Cells (J. Exp. Med. 179:81-89, 1994).						
	15	Graham, B.S. - Pathogenesis of Respiratory Syncytial Virus Vaccine-Augmented Pathology (Am. J. Respir. Crit. Care Med. 152:563-6, 1995)						
	18	Ulmer et al - Polynucleotide Vaccines (Current Opinion, Invest Drugs, 1993, 2: 983-989)						
	19	Chapman, B.S., Thayer, R.M.; Vincent, K.A. and Haigwood, N.L., - Effect of Intron A From Human Cytomegalovirus (Towne) Immediate-early Gene On Heterologous Expression In Mammalian Cells (Nucl. Acids. Res. 1991, 19: 3979-3986)						
	20	Nabel, G.J. et al - Direct Gene Transfer With DNA-Liposome Complexes In Melanoma: Expression, Biologic Activity, And Lack Of Toxicity In Humans (Proc. Natl. Acad. Sci. USA 90: 11307-11311, 1993)						
	21	Tang et al. - Genetic Immunization Is A Simple Method For Eliciting An Immune Response (Nature 1992, 356: 152-154)						
	22	Furth et al. - Gene Transfer Into Somatic Tissues By Jet Injection (Analytical Biochemistry, 1992, 205: 365-368)						
	23	Davis et al - Direct Gene Transfer In Skeletal Muscle: Plasmid DNA-based Immunization Against The Hepatitis B Virus Surface Antigen (Vaccine 1994, 12: 1503-1509)						
	24	Graham, B.S.; Perkins M.D.; Wright, P.F. and Karzon, D.T - Primary Respiratory Syncytial Virus Infection In Mice (J. Mod. Virol. 1988 26: 153-162)						
	25	Du, R.P. et al. - A Prototype Recombinant Vaccine Against Respiratory Syncytial Virus And Parainfluenza Virus Type 3 (Bio. Technology 12: 813-818, 1994)						
BW	26	Prince, G.A. et al. - The Pathogenesis Of Respiratory Syncytial Virus Infection In Cotton Rats (Ame. J. Pathol 93: 771-790, 1978)						
EXAMINER: Brian A. Hoffman				DATE CONSIDERED: 3/22/02				

*EXAMINER: Initial if reference considered, wh ther r not citation is in conf rmanace with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

Sheet 3 of 3

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO.: 1038-1003 MIS:jb	SERIAL NO.: 09/462,816
	APPLICANT: Xiaomao Li et al	
	FILING DATE: April 5, 2000	GROUP: 1633 1635

U.S. PATENT DOCUMENTS

INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
DW	27	Stott, E. J. et al - Human Respiratory Syncytial Virus Glycoprotein G Expressed From A Recombinant Vaccinia Virus Vector Protects Mice Against Live - Virus Challenge (Journal of Virology, (1986 Nov) 60 (2) 607-13)
	28	Hsu, K. H. et al Journal of Infectious Diseases, (1992 Oct) 166(4) 769-75
	29	Stott, E. J. et al - Immune And Histopathological Responses In Animals Vaccinated With Recombinant Vaccinia Viruses That Express Individual Genes of Human Respiratory Syncytial Virus (Journal of Virology, (1987 Dec) 61(12) 3855-61)
	30	Elango, N. et al - Resistance To Human Respiratory Syncytial Virus (RSV) Infection Induced By Immunization Of Cotton Rats With A Recombinant Vaccinia Virus Expressing The RSV G Glycoprotein (Proc. Natl Acad Sci, USA, (1986 Mar) 83(6) 1906-10)
	31	Roberts, S.R. et al -The Membrane-Associated And Secreted Forms Of The Respiratory Syncytial Virus Attachment Glycoprotein G Are Synthesized From Alternative Initiation Codons (Journal of Virology, (1994 Jul) 68(7) 4538-46)
	32	Nguyen, T. N. et al - Hydrophobicity Engineering To Facilitate Surface Display Of Heterologous Gene Products On Straphylococcus Xylosus (Journal of Biotechnology, (1995 Oct 16) 42(3) 207-19)
	33	Wathen, M. W. et al - Characterization Of A Novel Human Respiratory Syncytial Virus Chimeric FG Glycoprotein Expressed Using A Baculovirus Vector (Journal of General Virology, (1989 Oct) 70 (PT 10) 2625-35)
	34	Schrijver, R. S. et al - Comparison Of DNA Application Methods To Reduce BRSV Shedding In Cattle (Vaccine, vol 16, no.2-3, 2 January 1998, page 130-134)
DW	35	Johnson, T. R. et al - Priming With Secreted Glycoprotein G Of Respiratory Syncytial Virus (RSV) Augments Interleukin-5 Production and Tissue Eosinophilia After RSV Challenge (Journal of Virology, (1998 Apr) 72(4) 2871-80)
EXAMINER: <i>Brian R. Homan</i>		
DATE CONSIDERED: <i>3/22/02</i>		

*EXAMINER: Initial if reference considered, when the reference is not cited in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

* Will follow shortly

Received from <4165951163> at 2/1/02 1:49:50 PM [Eastern Standard Time]